Acute disseminated encephalomyelitis and COVID-19: A systematic synthesis of worldwide cases
- Laura Zelada-Ríos,
- Kevin Pacheco-Barrios(corresponding author),
- ,
- Cesar Yamunaqué-Chunga,
- Kelvin Álvarez-Toledo,
- Ricardo Otiniano-Sifuentes(corresponding author)
- docencia y atención especializada en epilepsia,
- Universidad Nacional Mayor de San Marcos,
- Department of Neurovascular Diseases,
- Universidad San Ignacio de Loyola,
- Harvard Medical School,
- Unidad de Investigación para la Generación y Síntesis de Evidencias en Salud
Open access
Publication Information
Output type
Original language
EnglishArticle number
577674Journal (Volume, Issue Number)
Journal of Neuroimmunology (Volume 359)Publication milestones
- Published - 15/10/2021
Publication status
ISSN
0165-5728Publication IDs
- Scopus: 85111977022
- PubMed: 34371208
Abstract
Acute disseminated encephalomyelitis (ADEM) has been reported after coronavirus disease 2019 (COVID-19). In this review, we systematically included worldwide reported cases on this association. We included 30 case reports (pediatric and adults) and explored epidemiological and clinical evidence. We described time to diagnosis, clinical, imaging, and laboratory features, response to treatment regimens, and differences regarding severity. Also, an original case report was presented. Neurologists must be alert to the occurrence of multifocal neurological symptoms with or without encephalopathy in patients recovered from COVID-19. Timely MRI studies should be performed to establish the diagnosis and to consider early corticosteroid-based treatment.